Concerning the liquid-to-solid phase transition in tauopathies [7,18], N-terminal inserts of tau can be considered the potential tunable therapeutic target to use when intervening in neurodegenerative disease progression at the early stages. The gene discussed is MAPT; the disease is tauopathy.